A Regeneron executive and one of its directors sold $1 million worth of stocks two days after President Donald Trump announced he was taking their therapeutic, recent filings from the Securities and Exchange Commission reveal.


Accountable Pharma, a campaign of the watchdog group Accountable.US, said the sales raised potential ethical concerns for the Trump administration and the drug company executives and called for an “investigation.”